Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line

Journal of Cell Science

Volumn 117, Issue 2, 2004, Pages 293-301

  Goldschneider, David ^a   Blanc, Etienne ^a   Raguénez, Gilda ^a   Barrois, Michel ^c   Legrand, Agnès ^b   Le Roux, Gwenaselle ^a   Haddada, Hedi ^b   Bénard, Jean ^a,c   Douc Rasy, Sétha ^a  

^a UMR 8126   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Apoptosis; Differentiation; Neuroblastoma; p53; p73

Indexed keywords

DOXORUBICIN; ISOPROTEIN; PROTEIN P21; PROTEIN P53; PROTEIN P73; VINCRISTINE;

ARTICLE; CELL LINE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; WILD TYPE;

CELL DIFFERENTIATION; CELL NUCLEUS; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENES, TUMOR SUPPRESSOR; HUMANS; IMMEDIATE-EARLY PROTEINS; MUTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 1642462384     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.00834     Document Type: Article

References (44)

1. Appella, E. and Anderson, C. W. (2000). Signaling to p53: breaking the posttranslational modification code. Pathol. Biol. (Paris) 48, 227-245.
2. Blaydes, J. P. and Wynford-Thomas, D. (1998). The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 16, 3317-3322.
3. Caron de Fromentel, C. and Soussi, T. (1992). TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4, 1-15.
4. Casciano, I., Mazzocco, K., Boni, L., Pagnan, G., Banelli, B., Allemanni, G., Ponzoni, M., Tonini, G. P. and Romani, M. (2002). Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death. Differ. 9, 246-251.
5. De Laurenzi, V., Raschella, G., Barcaroli, D., Annicchiarico-Petruzzelli, M., Ranalli, M., Catani, M. V., Tanno, B., Costanzo, A., Levrero, M. and Melino, G. (2000). Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J. Biol. Chem. 275, 15226-15231.
6. Dobbelstein, M., Wienzek, S., Konig, C. and Roth, J. (1999). Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18, 2101-2106.
7. Douc-Rasy, S., Barrois, M., Echeynne, M., Kaghad, M., Blanc, E., Raguenez, G., Goldschneider, D., Terrier-Lacombe, M. J., Hartmann, O., Moll, U., Caput, D. and Benard, J. (2002). DeltaN-p73alpha accumulates in human neuroblastic tumors. Am. J. Pathol. 160, 631-639.
8. Drané, P., Leblanc, V., Miro-Mur, F., Saffroy, R., Debuire, B. and May, E. (2002). Accumulation of an inactive form of p53 protein in cells treated with TNF alpha. Cell Death. Differ 9, 527-537.
9. Duriez, C., Falette, N., Audoynaud, C., Moyret-Lalle, C., Bensaad, K., Courtois, S., Wang, Q., Soussi, T. and Puisieux, A. (2002). The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene 282, 207-214.
10. Ferrandis, E., Da Silva, J., Riou, G.and Bénard, J. (1994). Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res. 15, 2256-2261.
11. Flores, E. R., Tsai, K. Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F. and Jacks, T. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564.
12. Giaccia, A. J. and Kastan, M. B. (1998). The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973-2983.
13. Gross, A., McDonnell, J. M. and Korsmeyer, S. J. (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13, 1899-1911.
14. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991). p53 mutations in human cancers. Science 253, 49-53.
15. Hood, J. K. and Silver, P. A. (2000). Diverse nuclear transport pathways regulate cell proliferation and oncogenesis. Biochim. Biophys. Acta 1471, M31-M41.
16. Ishimoto, O., Kawahara, C., Enjo, K., Obinata, M., Nukiwa, T. and Ikawa, S. (2002). Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 62, 636-641.
17. Jost, C. A., Marin, M. C. and Kaelin, W. G., Jr (1997). p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389, 191-194.
18. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F. and Caput, D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819.
19. Kartasheva, N. N., Contente, A., Lenz-Stoppler, C., Roth, J. and Dobbelstein, M. (2002). p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 21, 4715-4727.
20. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
21. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V. and Kastan, M. B. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491-7495.
22. Levine, A. J., Momand, J. and Finlay, C. A. (1991). The p53 tumour suppressor gene. Nature 351, 453-456.
23. Meplan, C., Mann, K. and Hainaut, P. (1999). Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. J. Biol. Chem. 274, 31663-31670.
24. Middeler, G., Zerf, K., Jenovai, S., Thulig, A., Tschodrich-Rotter, M., Kubitscheck, U. and Peters, R. (1997). The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene 14, 1407-1417.
25. Moll, U. M., LaQuaglia, M., Benard, J. and Riou, G. (1995). Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92, 4407-4411.
26. Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M. and Zambetti, G. (1996). Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16, 1126-1137.
27. Nakagawa, T., Takahashi, M., Ozaki, T., Watanabe, K. K., Todo, S., Mizuguchi, H., Hayakawa, T. and Nakagawara, A. (2002). Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol. Cell. Biol. 22, 2575-2585.
28. Nicolaev, A. Y., Li, M., Puskas, N., Qin, J. and Gu, W. (2003). Parc: a cytoplasmic anchor for p53. Cell 112, 29-40.
29. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W. and Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860.
30. Pozniak, C. D., Radinovic, S., Yang, A., McKeon, F., Kaplan, D. R. and Miller, F. D. (2000). An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289, 304-306.
31. Prives, C. and Hall, P. A. (1999). The p53 pathway. J. Pathol. 187, 112-126.
32. Puisieux, A. and Magaud, J. P. (1999). Mechanisms of BTG2 activity, a transcriptional target of p53: evidences and hypothesis. Bull. Cancer 86, 358-364.
33. Rouault, J. P., Falette, N., Guehenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., Shaw, P., Berger, R., Samarut, J., Magaud, J. P., Ozturk, M., Samarut, C. and Puisieux, A. (1996). Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat. Genet. 14, 482-486.
34. Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J. and Rutter, V. (1991). Nuclear localization is essential for the activity of p53 protein. Oncogene 6, 2055-2065.
35. Stiewe, T. and Putzer, B. M. (2002). Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 9, 237-245.
36. Stiewe, T., Zimmermann, S., Frilling, A., Esche, H. and Putzer, B. M. (2002). Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res., 62, 3598-3602.
37. Vossio, S., Palescandolo, E., Pediconi, N., Moretti, F., Balsano, C., Levrero, M. and Costanzo, A. (2002). DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21, 3796-3803.
38. Wolff, A., Technau, A., Ihling, C., Technau-Ihling, K., Erber, R., Bosch, F. X. and Brandner, G. (2001). Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex. Oncogene 20, 1307-1317.
39. Yang, A., Kaghad, M., Caput, D. and McKeon, F. (2002). On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18, 90-95.
40. Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., McKeon, F. and Caput, D. (2000). p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99-103.
41. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W. and Vogelstein, B. (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673-682.
42. Zaika, A. I., Kovalev, S., Marchenko, N. D. and Moll, U. M. (1999). Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59, 3257-3263.
43. Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Jr, Oren, M., Chen, J. and Lu, H. (1999). MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19, 3257-3266.
44. Zhu, J., Jiang, J., Zhou, W. and Chen, X. (1998). The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58, 5061-5065.